Nah , that's just the prune you ate this morning when ya saw Gale go up.
Just cover.. But your boss says keep posing.. Gotta make a living I gues .
It better or I'm trailer my horse to their office and let her explode road apples on their lawn, yep
Right ? I would think that if shorts shorted this far down, just cover and say it was good..
Leaves things to the imagination . There boss says keep posting negative stuff.
I do believe there is going to be a resolve meaning a rise in pps.
Two orphan drug statice designations and perhaps findings of what the problem was with the
Unusual request from IMDC . No shorts getting my shares , nope.
Don't flatter yourself soo much.. Funny how one feels his I.q.
Is higher when one guesses correctly.. Shorts won the battle
But not thewar.. There have been several bio's in the same spot.
Ziop for one... Jazz.. I would hate to be barowing shares.. yep
Wow good for you , profit 35k , hats off to ya.. Ya I still got a bag full of paper ..
But at least I own them..golly if I shorted and made that much , I'd move on.. Yep
Better data than Cpxx had.. Yep, it had prolong life of 2-4 months.
This one , 10-19 months prolong life.... And jazz bought Cpxx @ $30.00
they didn't even have it on the market yet.. Same senecio forming here..
Just sayin .. Glta.. I got lucky and got in at $1.44 this am.
Adam Feuerstein's Biotech Blog
RSS Feed for Adam Feuerstein's Biotech Blog
Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.
To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form....
.. Darn , there is a pic of him and he looks like j.c.'s kid .. Lmao!!!
Dang straight , two orphan drug Stacie . Still cooking..
One fresh word from our captain (lor3d save us) bout
Something found in IMDC request that lets them continue...wow 🚀
Now that said, 2 'different' orphan drug go ahead in the pipe line ... 1.50
IMHO .. Yep
Roche is generally regarded as the number one ophthalmology company in the world, and for a company the size of Eleven, is a dream partner.
The IND acceptance triggered a payment of $22.5 million. As part of the agreement, if the IND got approved before September, Eleven stood to receive this $22.5 million all in one go. Since it’s July, it did. If the approval came after September, the company would have had to forego $2.5 million of the payment. If Roche had had to conduct extra animal studies before approval, the payment would reduce to $5 million, with $15 million pending until the FDA thumbs up.
In short, it’s a best case scenario for Eleven.... Yep
We reckon there’s still plenty of room for gains. Here’s why.
Eleven is a development stage biotech with one lead focus, an IL-6 inhibitor called EBI-031. It’s an ocular disease indication, and the company is currently investigating its efficacy in two focus conditions – Diabetic Macular Edema and Uveitis. The latter is the lead of the two targets right now. Uveitis is an inflammation of the uvea, which is the three layered part of the eye that contains the iris. When inflamed it can cause blurry vision, and eventually (if left untreated) blindness. IL-6 is a cytokine that is associated with the initiation of an inflammatory response – it’s already a target in things like rheumatoid arthritis and is under investigation as a potential oncology target. Anyway, in this instance, EBI-031 is an IL-6 inhibitor – it binds to the IL-6 receptors stopping the IL-6 cytokines from doing so, and in turn, stopping the inflammatory process from kicking off. That’s the theory, at least.
So why all the bullish momentum as late? Well, the FDA just accepted what’s called an Investigational New Drug Application (IND) for the drug, which is a basically a green light for advancing the drug into human clinical trials. This is a pretty big step forward, but it wouldn’t normally bring with it gains to the tune of 1,000 percentage points. ......that is one reason for room higher , pps
Sometimes companies do bounce back from failure
Besides, there are other ways a company can recover from a so called "black swan" event. Look at Ziopharm, a company some suggest I love to hate.
Back in 2013 Ziopharm had a Phase III trial failure with palifosfamide which sent shares of ZIOP crashing from up around $6 down to less than $2. A short two years later Ziopharm caught fire again and climbed to almost $15 in 2015 as investor excitement about the CAR T space sent shares bubbling with Ziopharm attaining a market cap in excess of $1.5 billion USD.
Those that bought ZIOP in 2013 had the chance to realize gains of 500% or more if they played the contrarian game and bought the bad news of Ziopharm's trial failure. Perhaps those buying Galena around 40 to 50 cents currently will have a chance at similar gains in another year or two. ..
The IDMC recommends that this be investigated as quickly as possible and, in the meantime, that this information be disclosed only to any individual(s) with a need to know about the procedures used to clarify the current situation. Finally, the DMC requests that Galena Biopharma inform the IDMC members of the outcome of this investigation and any decision with respect to discontinuation of the clinical trial as soon as possible.
I don't want to read too much into the verbiage used, but it appears to me there is some "wiggle room" and that perhaps PRESENT could be re-started. However I consider that to be a faint hope and something that shareholders might cling onto even though it appears to me as ...
Roche will buy them before another milestone payment of 265 mill.
And let Ebio get royalties from sales.. The will buy them before that happens.
Sentiment: Strong Buy
This mb hasn't moved in weeks. Yahoo havin probs. Takes me a while but it's a hassle.
Go Ebio.. Quit selling .. Hold till $12-$16.. IMHO. Glta